Abstract:Purpose: The Asia-Pacific (APAC) region is a major focus for multinational clinical trials, although its cultural, linguistic, economic, and regulatory diversity pose significant challenges for trial conduct, particularly for academic clinical trials. Methods: We describe our experience running the investigator-initiated phase III randomized, fully accrued, Aspirin for Dukes C and high-risk Dukes B Colorectal cancer trial (ASCOLT, ClinicalTrials.gov identifier: NCT00565708, N = 1,587), studying the benefit of aspirin in resected high-risk colorectal cancer. ASCOLT opened in 2008 and is the first large academic adjuvant trial fully conducted in the APAC region. Centrally coordinated by the Trial Management Team at the National Cancer Centre Singapore, it has involved 74 sites across 12 APAC countries/regions, including five middle-income countries. Results: Challenges encountered included regulatory complexity, communication and logistical barriers, limited funding and resources, disparate experience and infrastructure across sites, recruitment holds because of changes in local laws, patient attrition, and disruptions caused by the COVID-19 pandemic. Over 100 contracts and 49 ethics board reviews were required, contributing to a lengthy prestudy preparation time of 2 years and start-up times of approximately 6 months per site. Some of the mitigating actions included engaging local cooperative groups (eg, the Australasian Gastro-Intestinal Trials Group in Australia and New Zealand) and seven contract research organizations to manage sites, regular communication with the central team, transition to electronic data management, and a centralized drug-dispensing system. Conclusion: To ensure an efficient and patient-centered clinical trials environment in the APAC region and sustained growth, we suggest coordinated approaches to harmonize regulatory processes, APAC academic oncology trials consortia to streamline processes and provide governance, and ongoing commitment from governments, funding agents, and industry.

The need for multicentre cardiovascular clinical trials in Asia

The necessary conduct: Exploratory multiregional clinical trials in East Asia

Global Randomized Trials: the Promise of India and China.

Multi-regional clinical trials and global drug development

Acute coronary syndrome in the Asia-Pacific region

Discussion of Developing China as Clinical Research Center in Asian-Pacific Region

Current Status of Multinational Clinical Trials in East Asia——Results of the Survey Using ClinicalTrials.gov

Availability of Cath Lab Facilities and Contemporary Inter-Hospital Transfer Patterns for the Management of Acute Coronary Syndromes Patients: Findings from the Epicor Asia Study

Transcatheter Aortic Valve Replacement in Asia: Present Status and Future Perspectives

Cardiovascular research in India: a perspective

Asia‐inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler

Research report on guidance for the multi-regional clinical trials

Focus on China: Should Clinicians Engage in Research? and Lessons from Other Countries.

Operational Challenges of an Asia-Pacific Academic Oncology Clinical Trial

Regulatory challenges associated with conducting multicountry clinical trials in resource-limited settings

Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators

How to make cardiology clinical trials more inclusive

Current Challenges of Asian National Children's Cancer Study Groups on Behalf of Asian Pediatric Hematology and Oncology Group

Key considerations for conducting Chinese medicine clinical trials in hospitals

Challenges from Variation across Regions in Cost Effectiveness Analysis in Multi-Regional Clinical Trials

Rationale, Design, and Baseline Characteristics of the EPICOR Asia Study (Long‐tErm follow‐uP of antithrombotic management patterns In Acute CORonary Syndrome patients in Asia)